Stock Events

Stock Events

Abeona Therapeutics 

$0
90
-$0.01-100% Friday 22:07

Statistics

Day High
-
Day Low
-
52W High
0
52W Low
0
Volume
-
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

20MayExpected
Q3 2024
Q4 2024
Q2 2025
Q3 2025
Q4 2025
Next
-0.63
0.15
0.93
1.71
Expected EPS
-0.335
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-63.73MNet Income

Analyst Ratings

$20.00Average Price Target
The highest estimate is 20.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AKC. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap26.03B
Biogen focuses on developing therapies for neurological and neurodegenerative diseases, directly competing with Abeona's gene therapy approach for similar disorders.
Pfizer
PFE
Mkt Cap161.09B
Pfizer has a broad portfolio including gene therapies targeting rare diseases, overlapping with Abeona's focus areas.
Sangamo Therapeutics
SGMO
Mkt Cap124.32M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, competing in the same space as Abeona for genetic disorders.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.67B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for rare diseases, directly competing with Abeona's rare disease focus.
Ultragenyx Pharmaceutical
RARE
Mkt Cap2.21B
Ultragenyx Pharmaceutical targets rare and ultra-rare diseases with its drug development, similar to Abeona's focus.
Sarepta Therapeutics
SRPT
Mkt Cap2.44B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics and gene therapy for rare diseases, competing with Abeona's gene therapy approach.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals engages in developing therapies for treating cystic fibrosis and other serious diseases, competing in the rare disease market with Abeona.
Novo Nordisk
NVO
Mkt Cap164.13B
Novo Nordisk focuses on a broad range of treatments including for rare diseases, potentially competing with Abeona in the gene therapy and rare disease market.

About

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in New York, New York.
Show more...
CEO
Mr. Michael Amoroso
Employees
76
Country
United States

Listings

STU
DE
PCJ.STU
F
DE
PCJ.F
XNAS
US
ABEO
LSE
GB
0H7R.LSE

0 Comments

Share your thoughts

FAQ

What is Abeona Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Abeona Therapeutics stocks are traded under the ticker AKC.
Is Abeona Therapeutics stock price growing?▼
AKC stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Abeona Therapeutics has showed a +249.09% increase.
When is the next Abeona Therapeutics earnings date?▼
Abeona Therapeutics is going to release the next earnings report on May 20, 2026.
What were Abeona Therapeutics earnings last quarter?▼
AKC earnings for the last quarter are -0.36 USD per share, whereas the estimation was -0.35 USD resulting in a -2.27% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Abeona Therapeutics revenue for the last year?▼
Abeona Therapeutics revenue for the last year amounts to 0 USD.
What is Abeona Therapeutics net income for the last year?▼
AKC net income for the last year is -63.73M USD.
How many employees does Abeona Therapeutics have?▼
As of April 12, 2026, the company has 76 employees.
In which sector is Abeona Therapeutics located?▼
Abeona Therapeutics operates in the Health & Wellness sector.
When did Abeona Therapeutics complete a stock split?▼
Abeona Therapeutics has not had any recent stock splits.
Where is Abeona Therapeutics headquartered?▼
Abeona Therapeutics is headquartered in New York, United States.